The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

ablacon.com

Founded Year

2015

Stage

Series B | Alive

Total Raised

$61.5M

Last Raised

$30M | 1 yr ago

About Ablacon

Ablacon builds a machine intelligence system to quantitatively and qualitatively understand and treat atrial fibrillation (AF). The company's algorithm uses artificial intelligence (AI) to analyze and visualize the flow of action potentials, or Electrographic Flow, within the heart in order to identify sources and drivers of AFib.

Ablacon Headquarter Location

4800 Wadsworth Blvd Suite 310

Wheat Ridge, Colorado, 80033,

United States

303-955-5620

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Ablacon

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Ablacon in 1 CB Insights research brief, most recently on Jul 26, 2019.

Expert Collections containing Ablacon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ablacon is included in 6 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

8,694 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

M

Medical Devices

11,001 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

D

Digital Health

12,795 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

D

Digital Health 150

150 items

The winners of the third annual CB Insights Digital Health 150.

H

Health IT

7,900 items

Ablacon Patents

Ablacon has filed 16 patents.

The 3 most popular patent topics include:

  • Cardiac arrhythmia
  • Cardiac electrophysiology
  • Cardiac anatomy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/24/2018

4/20/2021

Cardiac anatomy, Cardiac arrhythmia, Cardiac electrophysiology, Cardiology, Syndromes

Grant

Application Date

12/24/2018

Grant Date

4/20/2021

Title

Related Topics

Cardiac anatomy, Cardiac arrhythmia, Cardiac electrophysiology, Cardiology, Syndromes

Status

Grant

Latest Ablacon News

Ablacon Announces Martin Grasse as CEO and Clinical Study Progress

Jun 22, 2021

News provided by Share this article Share this article MENLO PARK, Calif., June 22, 2021 /PRNewswire/ -- Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer. Former CEO Duke Rohlen will continue with the company as Executive Chairman. "Marty has demonstrated exceptional leadership capabilities as Ablacon's Chief Operating Officer and in the process has earned the trust and respect of the entire team," said Rohlen. "Under his leadership, the company is well positioned to accomplish its ambitious goal of changing the atrial fibrillation treatment paradigm." Grasse has served as the company's Chief Operating Officer since April 2019. Prior to Ablacon, Grasse led business development at EPIX Therapeutics, which was acquired by Medtronic. Before EPIX, he worked in a variety of roles focused on electrophysiology and interventional cardiology technologies at Cibiem, Bridgepoint Medical (acquired by Boston Scientific), and St. Jude Medical. Grasse received an M.B.A. from Harvard Business School and a B.S. in Biomedical Engineering from the University of Wisconsin-Madison. "I'm thrilled with the progress that the Ablacon team has made over the past year and am excited for the months ahead as we focus on continuing to enroll our FLOW-AF clinical study and on enhancing our product offering through next generation research and development," said Grasse. "Ablacon's technology is unique in its ability to visualize the heart's Electrographic Flow, giving electrophysiologists a new layer of information with which to understand and treat arrhythmias like atrial fibrillation." The company also announces the 70th subject enrolled in the multicenter, randomized FLOW-AF clinical study on the use of Ablacon's product, AblaMap, in a persistent AF patient population. The study is designed to evaluate the technology's ability to identify sources of Electrographic Flow (EGF) and to guide elimination of these sources through ablation therapy. About Ablacon Ablacon, Inc. has offices in Menlo Park, California, Munich, Germany and Denver, Colorado, and has developed an advanced mapping system to guide the treatment of atrial fibrillation, the most frequent cardiac arrhythmia. The company's system uses advanced algorithms and machine learning to precisely localize and characterize the sources of AF and to guide targeted therapy by visualizing the Electrographic Flow within the cardiac chambers. The company's technology obtained CE Mark in 2018 and is currently being used in Europe.

Ablacon Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Ablacon Rank

  • When was Ablacon founded?

    Ablacon was founded in 2015.

  • Where is Ablacon's headquarters?

    Ablacon's headquarters is located at 4800 Wadsworth Blvd, Wheat Ridge.

  • What is Ablacon's latest funding round?

    Ablacon's latest funding round is Series B.

  • How much did Ablacon raise?

    Ablacon raised a total of $61.5M.

  • Who are the investors of Ablacon?

    Investors of Ablacon include Zeus Health, Western Technology Investment and Ajax Health.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.